3.62
5.24%
-0.20
After Hours:
3.669
0.049
+1.35%
Inventiva ADR stock is currently priced at $3.62, with a 24-hour trading volume of 87,454.
It has seen a -5.24% decreased in the last 24 hours and a +0.56% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.78 pivot point. If it approaches the $3.60 support level, significant changes may occur.
Inventiva ADR Stock (IVA) Financials Data
Inventiva ADR (IVA) Revenue 2023
IVA reported a revenue (TTM) of $14.46 million for the quarter ending June 30, 2023.
Inventiva ADR (IVA) Net Income 2023
IVA net income (TTM) was -$85.63 million for the quarter ending June 30, 2023.
Inventiva ADR (IVA) Cash Flow 2023
IVA recorded a free cash flow (TTM) of -$68.97 million for the quarter ending June 30, 2023.
Inventiva ADR (IVA) Earnings per Share 2023
IVA earnings per share (TTM) was -$2.0318 for the quarter ending June 30, 2023.
Inventiva ADR Stock (IVA) Latest News
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur
GlobeNewswire Inc.
Inventiva publie ses résultats annuels 2023
GlobeNewswire Inc.
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
GlobeNewswire Inc.
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
GlobeNewswire Inc.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
GlobeNewswire Inc.
About Inventiva ADR
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Cap:
|
Volume (24h):